Ex vivo susceptibility to new antimalarial agents differs among human-infecting Plasmodium species.

ABSTRACT: Several promising antimalarial drugs are currently being tested in human trials, such as artefenomel, cipargamin, ferroquine and ganaplacide. Many of these compounds were identified using high throughput screens against a single species of human malaria, Plasmodium falciparum, under the assumption that effectiveness against all malaria species will be similar, as has been observed for other antimalarial drugs. However, using our in vitro adapted line, we demonstrated recently that P. knowlesi is significantly less susceptible than P. falciparum to some new antimalarial drugs (e.g., cipargamin and DSM265), and more susceptible to others (e.g., ganaplacide). There is, therefore, an urgent need to determine the susceptibility profile of all human malaria species to the current generation of a

SUBMITTER: van Schalkwyk DA 

PROVIDER: S-EPMC8327131 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature